Tuesday, October 22nd from 19:30 to 21:00

P0157 Streamlined pre-formulation screening with minimal sample requirements and a turnaround time of 2 days enables development of AAV formulations with high efficiency
- Philipp Beck, Team Lead, Formulation Dev

P0057 Successful validation of capsid titer and host-cell derived DNA impurity assays extends our rAAV batch release QC portfolio
- Felicia Thoennissen, Senior Scientist, QC

P0229 From chemical to mechanical: A comparative analysis of cell lysis strategies for mammalian cells
- Ahmed Youssef, Senior Manager USP, PD

P0229 Our modular, fully scalable AAV purification process enables vector recoveries of up to 50% with built-in vector safety
- Melanie Langhauser, Team Lead, PD DSP

P0091 Successful capture chromatography DoE studies conducted for a range of AAV serotypes to reduce manufacturing costs and accelerate development - Melanie Langhauser, Team Lead, PD DSP

P0197 Two for one: A single QC assay to quantify two plasmid impurities (cap/kanR) across a number of serotypes reduces the time and costs for rAAV batch release
- Sonya Schermann, Sr Director Analytical Dev

P0059 Nanopore sequencing grants detailed insights into a small molecule's impact on encapsidated DNA composition during manufacturing platform development
- Kathrin Breunig, Scientist Tech Dev

P0153 Advancements in nanopore sequencing allow in-depth characterization of rAAV vector batches comparable to SMRT™ sequencing - Kathrin Breunig, Scientist Tech Dev

P0067 Assessing device compatibility through assay matrix approach ensures therapeutic consistency and patient welfare
- Huda Naas, Bio-Assay Dev Associate III

P0097 Qualification of an mRNA expression assay for GOI, stability insights, and process evolution detection
- Geeta Iyer, PD Manager, Assay Dev

Wednesday, October 23rd from 13:30 to 15:00

P0220 Considerations for AAV analytical comparability studies for products with low batch numbers
- Sonya Schermann, Sr Director Analytical Dev

P0068 Development and qualification of potency assay: guidelines and strategies - Huda Naas, Bio-Assay Dev Associate III